- Home
- KALA vs TENX Comparison
KALA vs TENX Comparison
Compare KALA & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- TENX
- Stock Information
- Founded
- KALA 2009
- TENX 1967
- Country
- KALA United States
- TENX United States
- Employees
- KALA N/A
- TENX N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- TENX Health Care
- Exchange
- KALA Nasdaq
- TENX Nasdaq
- Market Cap
- KALA 26.2M
- TENX 21.6M
- IPO Year
- KALA 2017
- TENX N/A
- Fundamental
- Price
- KALA $3.52
- TENX $6.08
- Analyst Decision
- KALA Strong Buy
- TENX Strong Buy
- Analyst Count
- KALA 3
- TENX 3
- Target Price
- KALA $14.00
- TENX $16.00
- AVG Volume (30 Days)
- KALA 55.2K
- TENX 9.3K
- Earning Date
- KALA 05-14-2025
- TENX 05-14-2025
- Dividend Yield
- KALA N/A
- TENX N/A
- EPS Growth
- KALA N/A
- TENX N/A
- EPS
- KALA N/A
- TENX N/A
- Revenue
- KALA N/A
- TENX N/A
- Revenue This Year
- KALA N/A
- TENX N/A
- Revenue Next Year
- KALA N/A
- TENX N/A
- P/E Ratio
- KALA N/A
- TENX N/A
- Revenue Growth
- KALA N/A
- TENX N/A
- 52 Week Low
- KALA $2.92
- TENX $2.77
- 52 Week High
- KALA $11.20
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- KALA 42.83
- TENX 56.92
- Support Level
- KALA $3.67
- TENX $6.00
- Resistance Level
- KALA $4.16
- TENX $6.31
- Average True Range (ATR)
- KALA 0.31
- TENX 0.26
- MACD
- KALA 0.05
- TENX 0.03
- Stochastic Oscillator
- KALA 34.20
- TENX 65.88
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.